GlassScriptPhysician profile
Allison L Holm
NPI 1114928231
$3,043.30
in general payments reported to CMS, 2019-2025
26 companies · $182 in 2025
The $182 reported for 2025 was less than what a typical Procedural Dermatology provider received nationally (typical 2025 total: $599).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $943 · 2020: $388 · 2021: $334 · 2022: $372 · 2023: $412 · 2024: $412 · 2025: $182.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $721 · Education: $285.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $720.51 |
| Education | $284.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $682.41 | 2019-2024 | Tremfya |
| Abbvie INC. | $526.61 | 2019-2024 | |
| Lilly USA, LLC | $301.87 | 2019-2025 | Taltz, Ebglyss |
| Sun Pharmaceutical Industries INC. | $163.05 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $143.34 | 2019-2023 | |
| Regeneron Healthcare Solutions, INC. | $131.26 | 2019-2025 | Dupixent |
| Dermira, INC. | $122.22 | 2019 | |
| Janssen Scientific Affairs, LLC | $112.13 | 2020 | |
| Galderma Laboratories, L.P. | $105.16 | 2019-2024 | |
| Incyte Corporation | $81.43 | 2022-2023 | Opzelura |
| Ucb, INC. | $72.03 | 2019-2024 | Bimzelx |
| Pfizer INC. | $67.09 | 2019-2023 | |
| Genzyme Corporation | $59.83 | 2021-2023 | |
| Celgene Corporation | $57.43 | 2019 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $49.48 | 2019 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $49.22 | 2019-2024 | Otezla |
| Vyne Pharmaceuticals INC. | $47.10 | 2020-2021 | |
| Leo Pharma INC. | $45.19 | 2019-2020 | |
| E.R. Squibb & Sons, L.L.C. | $45.17 | 2022-2023 | Sotyktu |
| Boehringer Ingelheim Pharmaceuticals, INC. | $43.81 | 2022-2023 | Cyltezo |
| Prugen, INC. Pharmaceuticals | $35.02 | 2019 | |
| Dermavant Sciences, INC. | $30.15 | 2022-2024 | Vtama |
| Verrica Pharmaceuticals INC. | $22.58 | 2024 | Ycanth |
| Allergan, INC. | $18.89 | 2019 | |
| Biofrontera INC. | $15.62 | 2019 | |
| Botanix Sb INC | $15.21 | 2025 | Sofdra |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Allison Holm listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.